Imricor logo — First & only suite of products for use in the iCMR to levera...

Imricor

First & only suite of products for use in the iCMR to leverage the superior soft tissue imaging capabilities of the MRI.

Founded 2006 United States Burnsville, United States 58 employees Post-IPO Equity Biotechnology, Health Care +1

General Information

Company Name Imricor
Founded Year 2006
Location United States Burnsville, United States
Employees 58
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Imricor. To contact Imricor, visit imricor.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Imricor compare?

A PDF of Imricor and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Imricor soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Imricor

Imricor, founded in 2006, aims to revolutionize the electrophysiology field with its innovative suite of products designed for use in the interventional cardiac magnetic resonance (iCMR) lab, making it the first and only of its kind. The company's slogan "First & only suite of products for use in the iCMR to leverage the superior soft tissue imaging capabilities of the MRI" underscores its commitment to leveraging MRI's imaging capabilities to enhance the outcomes and safety of cardiac ablation procedures. Imricor operates in the biotechnology, health care, and pharmaceutical industries. Imricor's pioneering approach has attracted significant attention from investors, with the most recent funding being a Post-IPO Equity investment on 01 October 2023. The details of the last investment, including the amount and the participating investors, were not disclosed. Imricor Medical Systems, Inc. is at the forefront of a promising intersection between cardiology, interventional radiology, and magnetic resonance imaging, presenting an intriguing opportunity for investors seeking to support advancements in the medical technology landscape.

Business keywords: electrophysiology, cardiac arrhythmias, MRI compatible tools, interventional medical technology, cardiac ablation procedures, MRI imaging, electrophysiology procedures, medical imaging technology

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
01 Oct 2023
Post IPO Equity Undisclosed -
21 Feb 2020
Post IPO Equity Undisclosed -
11 Sep 2019
Debt Financing Undisclosed -
24 May 2018
Venture Series Unknown Undisclosed -
29 Sep 2017
Venture Series Unknown Undisclosed -
17 Apr 2012
Seed Undisclosed -
16 Sep 2010
Venture Series Unknown Undisclosed -
12 Feb 2010
Seed Undisclosed -
03 Apr 2009
Debt Financing Undisclosed -
21 Jan 2009

Imricor Alternatives & Competitors

View All Alternatives
Imricor vs

Lesion Creation at the Speed of Light

Venture round
65 employees
Biotechnology, Health Care
Imricor vs

Pioneering compassionate, efficient, and minimally invasive tissue excision and biopsy for improved...

Venture round
Biotechnology, Health Care
Imricor vs
Clear Guide Medical
Clear Guide Medical United States

THE 𝐅𝐔𝐓𝐔𝐑𝐄 𝐎𝐅 𝐈𝐌𝐀𝐆𝐈𝐍𝐆 IS HERE ➞ 𝐀𝐈 𝐚𝐧𝐝 𝐀𝐑 Instrument Guidance

Grant
11 employees
Biotechnology, Health Care

FAQ About Imricor

First & only suite of products for use in the iCMR to leverage the superior soft tissue imaging capabilities of the MRI.
Imricor was founded in 2006.
Imricor is headquartered in Burnsville, United States.
Imricor operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on electrophysiology, cardiac arrhythmias, MRI compatible tools and interventional medical technology.
Imricor has approximately 58 employees.
Imricor has completed 10 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Imricor include CardioFocus, Suros Surgical Systems, Clear Guide Medical, Biosense Webster, Guerbet. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Imricor and CardioFocus are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Imricor, https://bouncewatch.com/company/imricor, updated 8 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes